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Background and objective Heterozygous mutations
in KCNA1 cause episodic ataxia type 1 (EA1), an ion
channel disorder characterised by brief paroxysms of
cerebellar dysfunction and persistent neuromyotonia. This
paper describes four previously unreported families with
EA1, with the aim of understanding the phenotypic
spectrum associated with different mutations.
Methods 15 affected individuals from four families
underwent clinical, genetic and neurophysiological
evaluation. The functional impact of new mutations
identiﬁed in the KCNA1 gene was investigated with in
vitro electrophysiology and immunocytochemistry.
Results Detailed clinical documentation, dating back to
1928 in one family, indicates that all patients manifested
episodic ataxia of varying severity. Four subjects from
three families reported hearing impairment, which has
not previously been reported in association with EA1.
New mutations (R167M, C185W and I407M) were
identiﬁed in three out of the four families. When
expressed in human embryonic kidney cells, all three
new mutations resulted in a loss of Kv1.1 channel
function. The fourth family harboured a previously
reported A242P mutation, which has not been
previously described in association with ataxia.
Conclusions The genetic basis of EA1 in four families
is established and this report presents the earliest
documented case from 1928. All three new mutations
caused a loss of Kv1.1 channel function. The ﬁnding of
deafness in four individuals raises the possibility of a link
between Kv1.1 dysfunction and hearing impairment. Our
ﬁndings broaden the phenotypic range associated with
mutations in KCNA1.
INTRODUCTION
Voltage-gated potassium channels (Kv channels)
play fundamental roles in controlling neuronal
excitability. The main pore-forming channel is com-
posed of four α subunits, of which approximately
40 subtypes are known, organised in 12 subfamilies
(Kv1–Kv12). They include two subgroups relevant
to disorders of peripheral nerve excitability, ataxia
and epilepsy: fast potassium channels (Kv1), and
slow potassium channels (Kv7). The Kv channel
also contains four intracellular auxiliary β subunits.
The speciﬁcity of α subunits for β subunits is con-
ferred by the cytosolic N-terminus of the α
subunit, and the combination of subunits inﬂuences
the expression and localisation of Kv channels, as
well as their gating and kinetic properties.1 2
Fast K+ channels that contain Kv1.1 subunits
usually occur as heterotetramers in combination with
Kv1.2 or Kv1.4 subunits. These channels are mostly
closed at resting membrane potential and have a rela-
tively low threshold for activation and rapid activa-
tion kinetics, but are slower than fast Na+ channels
(hence the term ‘delayed rectiﬁer’). K+ ion efﬂux,
driven by the electrochemical trans-membrane gradi-
ent, has a hyperpolarising effect on the membrane
potential and therefore limits neuronal excitability.3 4
In myelinated nerves, Kv1.1-containing K
+ channels
are densely expressed in the juxtaparanodal region of
the axon.2 Activation of fast K+ channels reduces the
resistance of the internodal membrane and limits
axonal hyperexcitability after an action potential.5 6
Dysfunction is thus expected to lead both to excessive
excitability of neurons and to an enhanced duration
of action potentials, which may in turn cause exces-
sive neurotransmitter release. These effects contrib-
ute to the repetitive activity and paraesthesiae elicited
by the Kv blocker 4-aminopyridine.
7 Of the many
other K+ channels, slow K+ channels encoded by
KCNQ genes are especially important in neurological
disease, such as benign familial neonatal epilepsy.8
They co-assemble to form outward rectifying cur-
rents that helps stabilise the membrane potential. In
neurones, these commonly exist as Kv7.2–Kv7.3 het-
eromers, which activate slowly and are non-
inactivating.3 9 Slow K+ channels are highly
expressed in myelinated nerve at the nodes of
Ranvier and the axonal initial segments,10 11 and in
the central nervous system they are abundant at the
axonal initial segments.10
Heterozygous mutations in the KCNA1 gene
(chromosome 12) encoding the α subunit of Kv1.1
result in episodic ataxia type 1.12 EA1 is a domin-
antly inherited condition characterised by brief
attacks of midline cerebellar disturbance including
limb ataxia, dysarthria, titubation, nystagmus,
tremor and gait incoordination. Episodes may be
triggered by startle, vigorous activity, change in
posture (eg, from sitting to standing), emotion,
hunger, alcohol or intercurrent illness. At the onset
of events, some of our patients describe the sensa-
tion of a ‘click’ or a ‘shock’ in their head. Episodes
last seconds to minutes and may be associated with
a feeling of apprehension or anxiety. Cerebellar
function is typically normal between attacks.
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However, almost all patients exhibit persistent neuromyotonia
which can be conﬁrmed on electromyography (EMG).13 14 An
increased incidence of epilepsy has also been reported in associ-
ation with EA1. Brain imaging in patients with EA1 is typically
unremarkable.15–18
Over 25 mutations have been identiﬁed in KCNA1, with func-
tional studies demonstrating a loss of channel function through
a dominant-negative mechanism.13 16 However, the full clinical
spectrum of EA1 is unknown. Here we describe new clinical
and genetic ﬁndings in four previously unreported families with
EA1. In addition to typical features of EA1, several individuals
reported hearing impairment. New heterozygous mutations in
KCNA1 were identiﬁed in three of the four families. All three
new mutations caused a loss of KV1.1 function. The fourth
family carried the A242P mutation which has previously been
reported in association with epilepsy and neuromyotonia but
not with ataxia.16
METHODS
Ethics approval was obtained from the Joint National Hospital
for Neurology and Neurosurgery/University College London
Ethics Committee and the University of Sydney Research Ethics
Committee for this project. All subjects provided written
informed consent. Patients were assessed clinically and, where
possible, nerve conduction studies and EMG were performed
according to a previously described protocol.13 Non-invasive
nerve excitability studies were also performed in this cohort,
and have been reported elsewhere.8
Gene sequencing
DNAwas extracted from venous blood or salivary samples using
standard procedures. PCR ampliﬁcation of DNA was performed
using newly designed primers and conditions (see online supple-
mentary data; tables S1 and S2) for KCNA1 reported in NCBI
(accession number NM000217). DNA sequencing was per-
formed using ABI BigDye terminator sequencing kit (V.1.1) and
an ABI 3730xl automated DNA sequencer. Analysis of results
was performed using ABI Seqscape (V.3.5) software. DNA from
198 control chromosomes was sequenced for comparison.
Functional expression
Cell culture
Human embryonic kidney cells (HEK-293) were grown in
Dulbecco modiﬁed Eagle medium supplemented with 10% fetal
bovine serum and 1% glutamax at 37°C with 5% CO2. Cells
were plated onto poly-D-lysine coated 10 mm cover slips.
KCNA1 and green ﬂuorescent protein (GFP) cDNA contained
within pMT2LF were co-transfected using lipofectamine2000
(Invitrogen). A total of 4 mg of DNA was used. All recordings
were made 36–72 h after transfection. To control for variability
in batches of transfections, recordings from wild-type (wt)
KCNA1-expressing cells were routinely intercalated with record-
ings from cells expressing mutant KCNA1.
Molecular biology
The identiﬁed human mutations were introduced into the corre-
sponding positions of the wt Kv1.1 cDNA construct contained
within the pMT2LF mammalian expression vector using a
PCR-based site-speciﬁc mutagenesis strategy (Stratagene
Quickchange). Mutant and wt clones were sequenced to verify
the presence of the mutations. Primer sequences are available
upon request.
Electrophysiology
Whole-cell patch clamp recordings were performed to record
potassium currents at room temperature. The external solution
contained (in mM): NaCl2 135; KCl 4; MgCl2 1; CaCl2 2;
HEPES 10. The pipette solution contained (in mM): NaCl 135;
KCl 2.5; EGTA 2; HEPES 10. Pipette resistance was 2–4 MΩ
when ﬁlled with intracellular solution. Cells were held at
−80 mV, and series resistance was not compensated. Cells with
series resistance above 10 MΩ were discarded. A –P/4 protocol
was used to subtract leak currents. Currents were recorded
using an Axopatch 200B ampliﬁer (Molecular Devices). Data
were acquired and analysed using LabView software (V.8.0,
National Instruments) with in-house acquisition programs
(DMK). Data were sampled at 20 kHz and ﬁltered at 5 kHz.
Graphs were plotted using Sigmaplot software (V.8.0, SPSS).
Statistical signiﬁcance was determined using one-way analysis of
variance.
Immunocytochemistry
HEK cells were co-transfected using lipofectamine with
pMT2LF KCNA1 and pcDNA3.1 GFP constructs 48 h prior to
immunocytochemistry. Cells were initially ﬁxed for 5 min with
2% and then 4% of paraformaldehyde, followed by washing
with 0.01% phosphate buffered saline solution (PBS). Cells
were permeabilised with 0.1% Triton X-100 in PBS for 5 min
and then incubated with 4% normal goat serum for 20 min.
Cells were incubated with the primary antibody, 1:500 rabbit
anti-human Kv1.1 (Abcam) which was mixed in 0.1% Triton
X-100 in PBS for 1 h. After washing, cells were incubated with
the secondary antibody, 1:1000 goat anti-rabbit alexa ﬂuor 546
(Invitrogen) for 1 h, washed and mounted in polyvinyl alcohol




Fifteen patients from four families in three countries were
studied (ﬁgure 1). All patients gave a history of brief episodes of
cerebellar dysfunction beginning in childhood or adolescence
(see online supplementary data, table S3). Clinical documenta-
tion of EA1 in Family C dates back to 1928 (ﬁgure 2). To our
knowledge this is the earliest clinical record of EA1. Several
interesting clinical features were noted. In most patients, the fre-
quency of ataxic episodes reached a peak during adolescence. A
common feature was exercise-induced ataxia, which would
disrupt sporting activities and, in several patients, resulted in the
inability to play sport or run at all. Vocation was signiﬁcantly
affected in four of 15 subjects. The proband in family C could
not speak publically in his role as a journalist because of
anxiety-induced attacks. The proband in family A, a naval
ofﬁcer, was required to signiﬁcantly modify his role signiﬁcantly
because of stress-induced ataxia. This subject also described
proximal muscle weakness during attacks, and ictal clinical
assessment veriﬁed this. The proband in family D experienced
seizures, which had not previously been described with this
mutation. Four subjects from three families reported hearing
impairment.
Clinical neurophysiology
Nerve conduction studies were performed in 10 of 15 affected
individuals (see online supplementary data, table 4). Apart from
one patient with a mild, unrelated neuropathy, routine sensory
and motor nerve conduction studies in patients with EA1
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showed normal motor conduction velocities and amplitudes.
Spontaneous repetitive discharges after a single stimulus were
seen in two of the 10 subjects. There was no evidence of
denervation on EMG, and voluntary contraction produced a
normal EMG interference pattern in patients. Neuromyotonia
was evident in 14 of 15 patients on EMG or clinical examin-
ation. The degree of myokymia/neuromyotonia varied and was
seen more often in facial muscles or small muscles of the hand.
Not all muscles samples in affected patients displayed spontan-
eous discharges.
Molecular genetics
In family A, a new heterozygous T to G substitution was identiﬁed
at nucleotide position 500. This results in the change of a posi-
tively charged arginine to a non-polar methionine at amino acid
position 167 (R167M). This mutation is located in the N-terminus
of the channel, at its junction with the transmembrane S1 domain.
In family B, a new heterozygous C to G substitution was identiﬁed
at nucleotide position 555, resulting in a substitution of cysteine to
tryptophan at amino acid position 185 (C185W) in the S1 trans-
membrane domain. In family C, a new heterozygous T to G substi-
tution was identiﬁed at nucleotide position 1221, resulting in the
substitution of isoleucine to methionine at amino acid position
407 (I407M) in the S6 transmembrane domain, in close proximity
to the start of the intracytoplasmic C-terminus. The amino acids
affected by each newly described mutation were highly conserved
across species (ENSEMBL genome browser; ﬁgure 3). These
nucleotide changes were not observed in 198 control chromo-
somes. In family D, a heterozygous T to G substitution was identi-
ﬁed at nucleotide position 500, resulting in the substitution of
alanine to proline at amino acid 242 (A242P). This mutation has
been previously reported in an unrelated kindred without ataxia.16
In vitro expression
Heterologous expression
No detectable potassium currents were observed when R167M
or C185W were expressed in HEK cells. In contrast, expression
of wt KV1.1 resulted in a slowly activating current evoked with
depolarising steps (ﬁgure 4). When expressed in HEK cells,
both the R167M and C185W mutants were detected with
anti-KV1.1 antibodies using immunoﬂuorescence techniques.
The distribution of immunoﬂuorescence was comparable to that
of wt KV1.1, implying normal trafﬁcking to the HEK cell mem-
brane. No intracellular aggregates were detected, conﬁrming
that the R167M and C185W mutants were not being retained
in the cytoplasm (ﬁgure 5).
Figure 2 Clinic letter dated 1928 describing assessment of subject
II:6 in family C.
Figure 1 Pedigree for families A, B, C and D. Black shapes denote affected family members. Asterisk indicates proband.
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Mutant and wt KV1.1 were co-expressed in HEK cells. Tail
currents recorded at −80 mV following repolarisation from differ-
ent voltages were used to characterise the voltage dependence of
activation. Both wt:R167M and wt:C185W resulted in K+ cur-
rents with a signiﬁcantly smaller peak current density compared
with wt alone (wt alone, 57.9±9.0 pA/pF, n=7; wt:R167M, 16.4
±2.4 pA/pF, n=8, p<0.001; wt:C185W, 17.3±4.1 pA/pF, n=5,
p<0.001). When co-expressed with wt, mutants also caused a sig-
niﬁcant positive shift in the V1/2 Max of the voltage dependence of
channel activation (wt:R167M=+10.0 mV; wt:C185W=
+4.4 mV, p<0.05; wt alone V1/2MAX=−32.8±0.9 mV).
Expression of I407M in HEK cells resulted in potassium cur-
rents with a signiﬁcantly smaller current density compared to wt
KV1.1 alone (I407M: 17.8±3.9 pA/pF, n=7, p<0.001). The
I407M mutant also caused a large positive shift in the voltage
dependence of activation (+21.4 mV, p<0.05) compared with wt
Kv1.1. When I407M was coexpressed with wt KV,1.1, the current
density was similar to I407M alone and signiﬁcantly lower than
wt alone (25.2±6.5 pA/pF, n=8, p<0.0001). Cells expressing wt
and I407M also exhibited a shift in the voltage dependence of
activation (as measured from the V1/2Max; +10.9 mV, p<0.05).
In summary, expression of all three mutants, R167M, C185W
and I407M is consistent with a pathogenic loss of function, a
change in activation threshold and a dominant-negative effect of
the mutant on wt KV1.1 subunits (ﬁgure 4).
DISCUSSION
Episodic ataxia type 1 typically presents with brief episodes of
cerebellar dysfunction with full resolution of cerebellar features
interictally. Continuous neuromyotonia is seen in most patients,
although the degree of neuromyotonia can vary widely. This
study describes four unreported families with a phenotype of
EA1. Several interesting new clinical observations are documen-
ted. Although seemingly a benign disorder, attacks of cerebellar
dysfunction can have a signiﬁcant impact on vocational duties,
participation in sport or daily activities. It is often the limitation
of function resulting from attacks that prompted patients to
seek medical assessment.
Clinical features
The proband in family A described proximal muscle weakness
during an attack, which is rarely reported in EA1. The proband
in family D experienced seizures, and this adds to the weight of
evidence implicating this mutation speciﬁcally, and KV1.1 dys-
function in general, in epilepsy. This mutation has previously
been described in association with epilepsy and neuromyotonia
alone,16 implying that other factors, genetic or environmental,
can affect the phenotype. Assessment for epilepsy should be
considered for all patients with EA1, in light of the increased
incidence of epilepsy in this disorder.
Figure 3 (i) Electrophoretograms
showing new mutations for families A,
B and C. Red=thymine,
green=adenosine, black=guanine,
blue=cytosine. (ii) Conservation of
KCNA1 amino acid sequence across
species. KCNA1 amino acids
152–196 are shown with the S1
segment outlined in grey. Arrows A,
R167; B, C185. (iii) Amino acids
381–413 with S6 segment outlined in
grey. Arrow C: I407 in S6.
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The presence of deafness in four patients is of particular interest
as KV1.1 is expressed in the auditory brainstem. Studies in KV1.1
null mice have demonstrated altered auditory processing, including
a failure to follow high-frequency sound stimulation.19 20
Furthermore, deafness is associated with mutations in other potas-
sium channel genes.21 Although the four individuals in this study
have not had audiological assessments, the ﬁnding suggests a link
between KV1.1 dysfunction and hearing impairment.
Neurophysiological studies
Published data on routine sensory and motor nerve conduction
studies in patients with EA1 show normal motor conduction
velocities and amplitudes,17 18 22–24 as was the case with our
cohort. Normal EMG interference pattern during voluntary
contraction was seen in patients, and interictal neuromyotonia
was readily detectable in all but one patient, as is documented
in the literature.16 22 23 Nerve excitability studies reported in
this cohort were able to detect changes speciﬁc to loss of fast
K+ channel function in vivo, and changes in axonal excitability
are sufﬁcient to differentiate them from normal controls with
100% sensitivity.14
Genetics
New KCNA1 mutations were identiﬁed in three of the families.
Evidence supporting pathogenicity of these mutations includes
the observations that all three mutations alter amino acids in
conserved regions of the gene; they segregate with the EA1
phenotype and were absent in control chromosomes.
Functional expression
All three mutations demonstrated a loss of KV1.1 channel func-
tion via a dominant-negative mechanism which is well estab-
lished in EA1. The ﬁnding of three new mutations in this
single-exon gene suggests that private family mutations may be
common in this disorder. Although heterologous expression
studies do not fully reveal the roles of KV1.1 in neuronal excit-
ability, we have recently shown that nerve excitability measure-
ment by threshold tracking provides direct evidence that
impaired KV1.1 function underlies the hyperexcitability of
motor axons in individuals with EA1.14
Paroxysmal nature of EA1
The reason for the intermittent manifestation of EA1 is not
known. Peripheral nerve excitability in this cohort is increased14
and a mouse model of EA1 has suggested excessive GABA
release at basket cell terminals in the cerebellar cortex.25
However, this does not explain the relationship to precipitants,
nor how the ictus spreads to involve the circuitry underlying cere-
bellar coordination throughout the body. Studies of EA1 in twins
have shown that variability in phenotype is a result of non-genetic
factors.26 Progressive ﬁxed or cerebellar syndromes are rarely
seen in patients with EA1. This is in contrast to patients with epi-
sodic ataxia type 2 (EA2), which is a dominantly inherited dis-
order due to mutations in CACNA1A encoding the presynaptic
Ca2+ channel Cav2.1 Patients with EA2 have long episodes of
ataxia, lasting hours or days, and may develop ﬁxed or progres-
sive cerebellar features that can be detected interictally. They do
not have neuromyotonia. EA2 is allelic with familial hemiplegic
migraine and spinocerebellar ataxia type 6 (SCA6), and there is
phenotypic overlap between these disorders.13
Treatment of EA1
Treatment for patients with EA1 is directed at symptom manage-
ment. Owing to the brevity of events, many patients do not
require medication for the ataxic events. Patients often learn to
modify their behaviour to avoid triggering episodes. Furthermore,
many report diminished frequency of episodes after adolescence.
Given the reduced fast K+ currents in these patients, an agent that
Figure 4 (A) Voltage step protocol and representative current traces elicited by applying a voltage step from a holding potential of −80 mV.
(B) Peak current density measured following depolarisation to ±10 mV (SEM). (C) Voltage dependence of activation estimated from tail currents
measured at −80 mV following depolarising steps to different potentials obtained in cells transfected with wt (n=7), I407 M (n=8), wt:I407M (n=5),
wt:R167M (n=7) and wt:C185W (n=5). Symbols as in panel A. Tail currents were sampled 1 ms after return to −80 mV. Error bars are SEM.
Recordings were made using low potassium internal solution.
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enhanced the current might be clinically useful. However, while
there are blockers of fast potassium channel function (aminopyri-
dines), there are no clinically useful agents that can increase this
current, unlike the situation with slow potassium channels, where
retigibine can enhance the current. Accordingly, therapies are
designed to modulate nerve excitability and possibly have indirect
effects on fast K+ channel function. If episodes are uncontrolled,
acetazolamide may diminish frequency and severity of episodes.
The severity of neuromyotonia is variable and may not require
treatment but carbamazepine, phenytoin and sulthiame have been
reported to be efﬁcacious.17 18 Finally, overexpression of wt Kv1.1
with a lentiviral vector has recently been used successfully in a
rodent model of neocortical epilepsy,27 potentially offering the
prospect of a targeted correction of the genetic defect in EA1.
However, gene delivery to a large area of the cerebellum for a rela-
tively benign condition presents substantial challenges.
Contributors Study concept and design: SET, SR, DB, MGH, DMK. Acquisition of data:
SET, SR, TG, DB, SS, CMS, RWL. Analysis and interpretation of data: SET, SR, SVT, DMK,
SS, RWL, DB. PG, MGH. Drafting of the manuscript: SET, SR, DB, DMK, MGH. Critical
revision of the manuscript for important intellectual content: SET, SR, DMK, SS, MGH.
Funding This work was supported by the Guarantors of Brain the British Medical
Association Vera Down Fellowship (ST), the Charities Aid Foundation Patrick
Berthoud Fellowship (ST), the University of Sydney (ST) and the UK Brain Research
Trust (ST), Wellcome Trust Research Training Fellowship (SR), UK Medical Research
Council grant number G0601943 (ST, SR, SS, MGH, DMK), The National Health and
Medical Research Council of Australia (ST, DB and CMS) and the Consortium for
Clinical Investigation of Neurological Channelopathies (CINCH) supported by NIH
RU54 RR019482 (ST, SR, SVT, DMK, MGH).
Competing interests None.
Ethics approval University of Sydney Human Research Ethics Committee, Joint
National Hospital for Neurology and Neurosurgery and Institute of Neurology Ethics
Committee.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
REFERENCES
1 Vacher H, Mohapatra DP, Trimmer JS. Localization and targeting of voltage-dependent
ion channels in mammalian central neurons. Physiol Rev 2008;88:1407–47.
2 Scherer SS, Arroyo EJ. Recent progress on the molecular organization of myelinated
axons. J Peripher Nerv Syst. 2002;7:1–12.
3 Baker M, Bostock H, Grafe P, et al. Function and distribution of three types of
rectifying channel in rat spinal root myelinated axons. J Physiol 1987;383:45–67.
4 Schwarz JR, Reid G, Bostock H. Action potentials and membrane currents in the
human node of Ranvier. Pﬂügers Arch 1995;430:283–92.
5 Bostock H, Cikurel K, Burke D. Threshold tracking techniques in the study of human
peripheral nerve. Muscle Nerve 1998;21:137–58.
6 Burke D, Kiernan MC, Bostock H. Excitability of human axons. Clin Neurophysiol
2001;112:1575–85.
7 Kocsis JD, Waxman SG, Hildebrand C, et al. Regenerating mammalian nerve ﬁbres:
changes in action potential waveform and ﬁring characteristics following blockage
of potassium conductance. Proc R Soc Lond B Biol Sci 1982;217:77–87.
8 Tomlinson SE, Bostock H, Grinton B, et al. In vivo loss of slow potassium channel
activity in individuals with benign familial neonatal epilepsy in remission. Brain
2012;135:3144–52.
9 Bostock H, Baker M. Evidence for two types of potassium channel in human motor
axons in vivo. Brain Res 1988;462:354–8.
10 Devaux JJ, Kleopa KA, Cooper EC, et al. KCNQ2 is a nodal K+ channel. J Neurosci
2004;24:1236–44.
11 Schwarz JR, Glassmeier G, Cooper EC, et al. KCNQ channels mediate IKs, a slow
K+ currentregulating excitability in the rat node of Ranvier. J Physiol 2006;
573:17–34.
12 Browne DL, Gancher ST, Nutt JG, et al. Episodic ataxia/myokymia syndrome is
associated with point mutations in the human potassium channel gene, KCNA1.
Nat Genet 1994;8:136–40.
13 Tomlinson SE, Hanna MG, Kullmann DM, et al. Clinical neurophysiology of the
episodic ataxias: insights into ion channel dysfunction in vivo. Clin Neurophysiol
2009;120:1768–76.
14 Tomlinson SE, Tan SV, Kullmann DM, et al. Nerve excitability studies characterize
Kv1.1 fast potassium channel dysfunction in patients with episodic ataxia type 1.
Brain 2010;133:3530–40.
15 Zuberi SM, Eunson LH, Spauschus A, et al. A novel mutation in the human
voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type
1 and sometimes with partial epilepsy. Brain 1999;122:817–25.
16 Eunson LH, Rea R, Zuberi SM, et al. Clinical, genetic, and expression studies of
mutations in the potassium channel gene KCNA1 reveal new phenotypic variability.
Ann Neurol 2000;48:647–56.
17 Brunt ER, Van Weerden TW. Familial paroxysmal kinesigenic ataxia and continuous
myokymia. Brain 1990;113:1361–82.
18 Vaamonde J, Artieda J, Obeso JA. Hereditary paroxysmal ataxia with
neuromyotonia. Mov Disord 1991;6:180–2.
19 Brew HM, Hallows JL, Tempel BL. Hyperexcitability and reduced low threshold
potassium currents in auditory neurons of mice lacking the channel subunit Kv1.1.
J Physiol 2003;548:1–20.
20 Kopp-Scheinpﬂug C, Fuchs K, Lippe WR, et al. Decreased temporal precision of
auditory signaling in Kcna1-null mice: an electrophysiological study in vivo.
J Neurosci 2003;23:9199–207.
21 Maljevic S, Wuttke TV, Seebohm G, et al. Kv7 channelopathies. Pﬂugers Arch
2010;460:277–88.
22 Van Dyke DH, Griggs RC, Murphy MJ, et al. Hereditary myokymia and periodic
ataxia. J Neurol Sci 1975;25:109–18.
23 Hanson PA, Martinez LB, Cassidy R. Contractures, continuous muscle discharges,
and titubation. Ann Neurol 1977;1:120–4.
24 Gancher ST, Nutt JG. Autosomal dominant episodic ataxia: a heterogeneous
syndrome. Mov Disord 1986;1:239–53.
25 Herson PS, Virk M, Rustay NR, et al. A mouse model of episodic ataxia type-1. Nat
Neurosci 2003;6:378–83.
26 Graves TD, Rajakulendran S, Zuberi SM, et al. Nongenetic factors inﬂuence severity
of episodic ataxia type 1 in monozygotic twins. Neurology 2010;27:367–72.
27 Wykes RC, Heeroma JH, Mantoan L, et al. Optogenetic and potassium channel
gene therapy in a rodent model of focal neocortical epilepsy. Sci Transl Med
2012;4:161ra152.
Figure 5 The Kv1.1 antibody detects the channel and the mutants,
R167M and C185W in transfected human embryonic kidney (HEK) cells.
The antibody does not detect any Kv1.1 channel in the HEK cells
transfected with green ﬂuorescent protein only (bottom panel).
1112 Tomlinson SE, et al. J Neurol Neurosurg Psychiatry 2013;84:1107–1112. doi:10.1136/jnnp-2012-304131
Movement disorders
